Clinical trial

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

NCT06719011

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-12-03

PhasePHASE1

Study timeline

Study start (actual)2024-12-03Date precision: day

Registry last updated2026-08-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Obesityunresolved

Overweightunresolved

Interventions

NNC0174-1213 ADRUG

Cagrilintide BDRUG

Placebo A (NNC0174 1213 A)DRUG

Sponsors & collaborators

Novo Nordisk A/Slead sponsor

Mapped research locations

San AntonioTexas, United States1 Salt Lake CityUtah, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06719011 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.